There’s A 14% Slump Ahead For AstraZenenca plc

Recovery might be coming for AstraZeneca plc (LON: AZN), but it’ll take a few more years.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since Pascal Soriot took the helm at AstraZeneca (LSE: AZN) (NYSE: AZN.US) in October 2012, investor confidence has been returning strongly. The share price is up 23% over the past 12 months, to 4,175p, and over three years it has picked up 35% against the FTSE’s 10% — and that’s impressive for a company that has seen earnings falling for two years in a row.

Earnings falling

AZNIn fact, earnings per share (EPS) slumped by 26% in 2013, in part due to the expiry of patents on some key drugs and increasing competition from generic alternatives.

With the shares on the rise again, you might think there’s a return to growth forecast. Well, no, there isn’t. The current consensus still suggests a further 14% fall in earnings for 2014, with a 2% slip to follow in 2015 — and that puts the shares on a forward P/E for 2015 of 16, which some will see as a bit high.

And we must remember that forecasts for rival GlaxoSmithKline, which faces the same industry problems, are looking a good bit better.

Past the bottom?

The trend of forecasts for AstraZeneca has been slipping, too. The same analysts who are now predicting 2014 EPS of 258p were touting 335p just a year ago, but at least it has firmed up a little in the past month, from a low of 255p.

Forecasts for 2015 have also started to reverse their downward movement, as updates from the company have started sounding a bit more bullish — as recently as last week, speaking of first-quarter results, Mr Soriot said “We are investing in our rapidly progressing pipeline and the key platforms that are the backbone of our strategy to return to growth“.

Against that optimism, however, there’s still a wide spread of opinions between individual analysts’ forecasts — though we’re awaiting adjustments after that first-quarter update.

ThumbDownOn the actual recommendation front, out of a sample of 32 commentators, five have posted Buy recommendations with 11 suggesting Sell. That puts a fairly large proportion of them in the remaining 15 who are sitting on the Hold fence — presumably waiting for concrete news before endorsing (or refuting) the company’s upbeat outlook.

Wait and see

What do I think? Well, GlaxoSmithKline looks the better investment to me right now, with better earnings and dividend forecasts, a lower P/E valuation, and that positive-looking Novartis deal in the bag.

On the whole, then, I’m with the “wait and see” crowd, and I think the short-term optimism might be overdone.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan does not own any shares in AstraZeneca or GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »